Publication: Long-Term Benzodiazepine Prescription during Maintenance Therapy of Individuals with Psychosis Spectrum Disorders - Associations with Cognition and Global Functioning
| dc.contributor.author | Savic, Bojana (57216800047) | |
| dc.contributor.author | Jerotic, Stefan (57207916809) | |
| dc.contributor.author | Ristic, Ivan (57191339222) | |
| dc.contributor.author | Zebic, Mirjana (16508355400) | |
| dc.contributor.author | Jovanovic, Nikolina (22956210600) | |
| dc.contributor.author | Russo, Manuela (35764063200) | |
| dc.contributor.author | Maric, Nadja P. (57226219191) | |
| dc.date.accessioned | 2025-06-12T13:33:05Z | |
| dc.date.available | 2025-06-12T13:33:05Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Background Cognitive difficulties have a significant impact on life functioning and overall well-being in patients with psychosis spectrum disorders (PSDs). There are indications that continuous use of benzodiazepines (BZDs) in various patient groups has a detrimental effect on cognition. Our aim was to explore the association between long-term BZD prescription, global functioning, and cognitive functioning in persons with PSD. Methods This exploratory study included 55 PSD patients, recruited from 2 outpatient services in Serbia. Patients were grouped into BZD long-term prescription group and BZD-other group. Brief Psychiatric Rating Scale was used for symptom assessment, functioning was measured by Global Assessment and Functioning Scale, and cognition was assessed by the Global Assessment of Functioning-Cognition in Schizophrenia Scale. Results The sample comprised 52.7% patients who were prescribed with BZD for 6 months or more continually (29/55), with a mean daily dose of 3.16 ± 0.66 mg lorazepam equivalents. There were no differences between study groups in any of the sociodemographic characteristics, duration of illness, or antipsychotic daily dosages. The BZD long-term prescription group had lower global (P < 0.01) and cognitive functioning (P < 0.01), higher Brief Psychiatric Rating Scale scores (1.86 vs 1.58, respectively, P < 0.01), and more psychotropic drugs prescribed on a daily basis than the other group (median: 4 vs 2, respectively, P < 0.01). Conclusions The study explored a topic that continues to be underresearched, especially in the Balkans. Prospective studies and comprehensive cognitive batteries are needed to further elucidate the associations between polypharmacy, long-term BZD use, cognitive functioning, and global functioning during maintenance therapy of individuals with PSD. © Wolters Kluwer Health, Inc. All rights reserved. | |
| dc.identifier.uri | https://doi.org/10.1097/WNF.0000000000000442 | |
| dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106400123&doi=10.1097%2fWNF.0000000000000442&partnerID=40&md5=9333fd787d2d5b5b5d3782f23c18815a | |
| dc.identifier.uri | https://remedy.med.bg.ac.rs/handle/123456789/4211 | |
| dc.subject | benzodiazepine therapy | |
| dc.subject | BPRS | |
| dc.subject | cognition | |
| dc.subject | functioning | |
| dc.subject | GAF | |
| dc.subject | psychosis | |
| dc.title | Long-Term Benzodiazepine Prescription during Maintenance Therapy of Individuals with Psychosis Spectrum Disorders - Associations with Cognition and Global Functioning | |
| dspace.entity.type | Publication |
